PENNINGTON, N.J. and
SAN DIEGO, May 17, 2021 /PRNewswire/ -- OncoSec Medical
Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today
announced the appointment of Robert M.
Schinagl, Ph.D., a biotech industry veteran with over 20
years of experience, as Vice President of Program and Alliance
Management, effective May 17,
2021.
"We are thrilled to welcome Dr. Schinagl to OncoSec's management
team as the company continues to make progress in the development
of our lead product candidate, TAVO™," said Daniel J. O'Connor, President and Chief
Executive Officer of OncoSec. "As we actively seek opportunities
through strategic partnerships and uphold our mission to bring
transformative solutions to patients in need, we believe Dr.
Schinagl's significant leadership expertise in project and alliance
management will help drive OncoSec in the direction of joining
forces and leveraging a fully-integrated immuno-oncology
platform."
Dr. Schinagl added, "I am excited to work with Dan and the
OncoSec leadership team at a pivotal point in the Company's history
as it continues to advance TAVO through clinical development. I
look forward to helping the Company continue its positive momentum
and working with potential partners to bring its ground-breaking
science to patients not benefitting from currently available cancer
treatments."
Dr. Schinagl most recently served as Chief Operating Officer at
Prothex Pharma, Inc., where he was responsible for strategy,
clinical development, regulatory affairs, business development, and
portfolio and alliance management. He led all regulatory and health
authority interactions and led drug development teams, driving
collaboration among employees, consultants, academic experts,
vendors and partners. Dr. Schinagl supported business development
by assessing in-license opportunities and coordinating due
diligence efforts for out-licensing, and he was a member of the
Prothex's joint development committees.
Prior to Prothex, Dr. Schinagl held a variety of project and
alliance leadership positions at Drais Pharmaceuticals, Eli Lilly,
ImClone Systems, Yamanouchi Pharma America, Quintiles Advanced
Phase Solutions, and Osiris Therapeutics. In these roles, Dr.
Schinagl led a range of leading drug development programs largely
focused on oncology. Dr. Schinagl earned doctorate and master's
degrees in bioengineering at the University of
California, San Diego and his bachelor's degree in
bioengineering at the University of Pennsylvania.
As of May 17, 2021, Dr. Schinagl
will be granted an initial grant of 35,000 stock options. These
stock options will have an exercise price equal to the closing
price of the Company's common stock on the date of grant and will
be 25% vested on the date of grant, with the remaining 75% vesting
quarterly over a two-year period. These stock options were granted
as an inducement to Dr. Schinagl entering into employment with the
Company in accordance with NASDAQ Listing Rule 5635(c)(4).
About TAVO™
OncoSec's gene therapy technology
combines TAVO (tavokinogene telseplasmid), a DNA plasmid-based
interleukin-12 (IL-12), with an intra-tumoral electroporation gene
delivery platform to achieve endogenous IL-12 production in the
tumor microenvironment that enables the immune system to target and
attack tumors throughout the body. TAVO has demonstrated a
local and systemic anti-tumor response in several clinical trials,
including the pivotal Phase 2b trial
KEYNOTE-695 for metastatic melanoma and the KEYNOTE-890 Phase 2
trial in triple negative breast cancer (TNBC). TAVO has
received both Orphan Drug and Fast-Track Designation by the
U.S. Food & Drug Administration for the treatment of
metastatic melanoma.
About OncoSec Medical Incorporated
OncoSec Medical
Incorporated (the "Company," "OncoSec," "we" or "our") is a
biotechnology company focused on developing cytokine-based
intratumoral immunotherapies to stimulate the body's immune system
to target and attack cancer. OncoSec's lead immunotherapy
investigational product candidate – TAVO™ (tavokinogene
telseplasmid) – enables the intratumoral delivery of DNA-based
interleukin-12 (IL-12), a naturally occurring protein with
immune-stimulating functions. The technology, which employs
electroporation, is designed to produce a controlled, localized
expression of IL-12 in the tumor microenvironment, enabling the
immune system to target and attack tumors throughout the body.
OncoSec has built a deep and diverse clinical pipeline utilizing
TAVO™ as a potential treatment for multiple cancer indications
either as a monotherapy or in combination with leading checkpoint
inhibitors; with the latter potentially enabling OncoSec to address
a great unmet medical need in oncology: anti-PD-1 non-responders.
Results from recently completed clinical studies of TAVO™ have
demonstrated a local immune response, and subsequently, a systemic
effect as either a monotherapy or combination treatment approach
along with an acceptable safety profile, warranting further
development. In addition to TAVO™, OncoSec is identifying and
developing new DNA-encoded therapeutic candidates and tumor
indications for use with its new Visceral Lesion Applicator (VLA),
to target deep visceral lesions, such as liver, lung or pancreatic
lesions. For more information, please
visit www.oncosec.com.
TAVO™ is a trademark of OncoSec Medical Incorporated.
Risk Factors and Forward-Looking Statements
This
release, as well as other information provided from time to time by
the Company or its employees, may contain forward-looking
statements that involve a number of risks and uncertainties that
could cause actual results to differ materially from those
anticipated in the forward-looking statements. Forward-looking
statements provide the Company's current beliefs, expectations and
intentions regarding future events and involve risks, uncertainties
(some of which are beyond the Company's control) and assumptions.
For those statements, we claim the protection of the safe harbor
for forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. You can identify forward-looking
statements by the fact that they do not relate strictly to
historical or current facts. These statements may include words
such as "anticipate," "believe," "could," "estimate," "expect,"
"intend," "may," "plan," "potential," "should," "will" and "would"
and similar expressions (including the negative of these terms).
Although we believe that expectations reflected in the forward-
looking statements are reasonable, we cannot guarantee future
results, levels of activity, performance or achievements. The
Company intends these forward-looking statements to speak only at
the time they are published on or as otherwise specified, and does
not undertake to update or revise these statements as more
information becomes available, except as required under federal
securities laws and the rules and regulations of the Securities
Exchange Commission ("SEC"). In particular, you should be aware
that the success and timing of our clinical trials, including
safety and efficacy of our product candidates, patient accrual,
unexpected or expected safety events, the impact of COVID-19 on the
supply of our candidates or the initiation or completion of
clinical trials and the usability of data generated from our trials
may differ and may not meet our estimated timelines. Please refer
to the risk factors and other cautionary statements provided in the
Company's Annual Report on Form 10-K for the fiscal year ended
July 31, 2019 and subsequent periodic
and current reports filed with the SEC (each of which can be found
at the SEC's website www.sec.gov), as well as other factors
described from time to time in the Company's filings with the
SEC.
Company Contact
Brian
Leuthner
Chief Operating Officer
investors@oncosec.com
Media Contact
Patrick
Bursey
LifeSci Communications
+1-646-970-4688
pbursey@lifescicomms.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/oncosec-appoints-robert-m-schinagl-phd-as-vice-president-of-program-and-alliance-management-301292335.html
SOURCE OncoSec Medical Incorporated